Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2012 1
2014 1
2015 2
2016 4
2017 11
2018 6
2019 11
2020 10
2021 11
2022 13
2023 7
2024 9
2025 24
2026 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

101 results

Results by year

Filters applied: . Clear all
Page 1
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.
Vulsteke C, Adra N, Danchaivijitr P, Sabadash M, Rodriguez-Vida A, Zhang Z, Atduev V, Göger YE, Rausch S, Kang SH, Loriot Y, Bedke J, Galsky MD, O'Donnell PH, von Amsberg G, Alimohamed N, Sulimka G, Gupta S, Paramonov V, Nakane K, Mihm M, Meng C, Huang CD, Ramamurthy C, Homet Moreno B, Ullén A; KEYNOTE-905/EV-303 Investigators. Vulsteke C, et al. N Engl J Med. 2026 Apr 2;394(13):1257-1269. doi: 10.1056/NEJMoa2511674. Epub 2026 Feb 18. N Engl J Med. 2026. PMID: 41707170 Clinical Trial.
Harnblasenkarzinom - eine Erkrankung im Wandel.
Casuscelli J. Casuscelli J. MMW Fortschr Med. 2025 Oct;167(17):5. doi: 10.1007/s15006-025-5266-z. MMW Fortschr Med. 2025. PMID: 41068369 German. No abstract available.
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer.
Klümper N, Tran NK, Zschäbitz S, Hahn O, Büttner T, Roghmann F, Bolenz C, Zengerling F, Schwab C, Nagy D, Toma M, Kristiansen G, Heers H, Ivanyi P, Niegisch G, Grunewald CM, Darr C, Farid A, Schlack K, Abbas M, Aydogdu C, Casuscelli J, Mokry T, Mayr M, Niedersüß-Beke D, Rausch S, Dietrich D, Saal J, Ellinger J, Ritter M, Alajati A, Kuppe C, Meeks J, Vera Badillo FE, Nakauma-González JA, Boormans J, Junker K, Hartmann A, Grünwald V, Hölzel M, Eckstein M. Klümper N, et al. Among authors: casuscelli j. J Clin Oncol. 2024 Jul 10;42(20):2446-2455. doi: 10.1200/JCO.23.01983. Epub 2024 Apr 24. J Clin Oncol. 2024. PMID: 38657187 Free PMC article.
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.
De Santis M, Palou Redorta J, Nishiyama H, Krawczyński M, Seyitkuliev A, Novikov A, Guerrero-Ramos F, Zukov R, Kato M, Kawahara T, Goeman L, Puente J, Hellmis E, Powles T, Radziszewski P, Gust KM, Vasey P, Bigot P, Fradet Y, Hunting J, Armstrong J, Boulos S, Hois S, Shore ND; POTOMAC Investigators. De Santis M, et al. Lancet. 2025 Nov 8;406(10516):2221-2234. doi: 10.1016/S0140-6736(25)01897-5. Epub 2025 Oct 17. Lancet. 2025. PMID: 41115436 Clinical Trial.
[Systemic treatment of bladder cancer].
Tamalunas A, Schulz GB, Rodler S, Apfelbeck M, Stief CG, Casuscelli J. Tamalunas A, et al. Among authors: casuscelli j. Urologe A. 2021 Feb;60(2):247-258. doi: 10.1007/s00120-020-01420-5. Urologe A. 2021. PMID: 33398384 Review. German.
[Systemic treatment options for metastatic prostate cancer].
Aydogdu CD, Casuscelli J. Aydogdu CD, et al. Among authors: casuscelli j. MMW Fortschr Med. 2024 Nov;166(19):64-69. doi: 10.1007/s15006-024-4313-5. MMW Fortschr Med. 2024. PMID: 39511096 Review. German. No abstract available.
Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data.
Unterrainer LM, De Leiris N, Unterrainer M, Delker A, Hempel L, Ells Z, Kunte SC, Zahner J, Holzgreve A, Zacherl MJ, Sheikh GT, Casuscelli J, Leenhardt J, Pienta KJ, Jacquet E, Laramas M, Long J, Faure M, Reboulet G, Paller CJ, Mercier A, Solnes LB, Kiraz K, Ilhan H, Gafita A, Djaileb L. Unterrainer LM, et al. Among authors: casuscelli j. J Nucl Med. 2025 Jul 1;66(7):1054-1060. doi: 10.2967/jnumed.124.269431. J Nucl Med. 2025. PMID: 40274370
Longer Telomere Length and Renal Cell Carcinoma.
Casuscelli J, Hakimi AA. Casuscelli J, et al. Eur Urol. 2017 Nov;72(5):755-756. doi: 10.1016/j.eururo.2017.08.008. Epub 2017 Sep 18. Eur Urol. 2017. PMID: 28927584 No abstract available.
Refining prognostic stratification in salvage radiotherapy for prostate cancer: a retrospective multicenter cohort study using PSMA-PET and machine learning.
Medici F, Aebersold DM, Casuscelli J, Emmett L, Fanti S, Farolfi A, Guckenberger M, Hruby G, Koerber SA, Thoma SA, Peeken JC, Rogowski P, Scharl S, Shelan M, Spohn SKB, Strouthos I, Vogel M, Wiegel T, Zamboglou C, Schmidt-Hegemann NS, Morganti AG, Cilla S. Medici F, et al. Among authors: casuscelli j. Radiother Oncol. 2025 Nov;212:111113. doi: 10.1016/j.radonc.2025.111113. Epub 2025 Aug 21. Radiother Oncol. 2025. PMID: 40849083 Free article.
101 results